Announcement PDF ASX Announcement – 13 October 2025 Resonance Health Ltd ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com Investor Strategy Day Briefing - Webinar Resonance Health Limited (Resonance or Company) (ASX: RHT) has today released an investor strategy day presentation which is enclosed with this announcement. Investors are invited to join a live webcast and Q&A hosted by Andrew Harrison, MD & CEO, Benjamin Carruthers, CFO, and Dr Helen Pavitt, VP Clinical Trials today, 13 October 2025 at 10:00 a.m. Australian Western (Perth) Time (AWST). You can attend via the link https://investors.resonancehealth.com/webinars/Ky0poy-resonance-health-group- strategy-briefing-day Additionally, a video recording of the presentation will be available within 24 hours following the presentation at the Resonance Health Investor Centre homepage: https://investors.resonancehealth.com/ This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact: Andrew Harrison – Chief Executive Officer E: andrewh@resonancehealth.com P: +61 (0)8 9286 5300 About Resonance Health Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development. Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include: § FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment. § FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®. § HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease. § HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease. Page 2 § LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat. § CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. The Company has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest. Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn. 1 Resonance Health Investor Strategy Day 13 October 2025 Andrew Harrison MD & CEO Benjamin Carruthers CFO Dr Helen Pavitt VP, Clinical Trials Agenda 1. Introduction & Strategy Overview Andrew Harrison 3 2. Financial Overview Benjamin Carruthers 17 3. Resonance Clinical & TrialsWest Business Dr Helen Pavitt 25 4. Panel Q&A Andrew Harrison, Benjamin Carruthers & Helen Pavitt Topic Presenter Slide # 3 Resonance Health Introduction and Strategy Overview Andrew Harrison MD & CEO Significant revenue growth and diversification since FY23 FY23 FY26 Total Revenue $4.4M Total Revenue Guidance ~$17M ✓ FY23–FY26 strong revenue growth (~45% CAGR) ✓ Profitable ~$2M EBITDA ✓ Diversified revenue ✓ Customer, clinical, and technical synergies We participate in a number of areas of the global clinical trial ecosystem… We have significantly expanded our addressable global market… New Imaging Endpoints for Metabolic & Obesity VAT, SAT, MRE 2023 MRI Liver Iron Measurement market ~ $200M + liver fat market ~$300m + + obesity and liver fibrosis >$500m + CRO and Investigator site services ~$70b Operating in markets with strong tailwinds globally & locally Global Clinical Trial Market Australian Clinical Trial Market Key Drivers - Globally ✓ Increasing rapidity of technological breakthroughs ✓ Shortening development timeframes ✓ Increase in outsourcing of trials ✓ Increase in efficiency of non-hospital trials ✓ Approvals and regulatory system ✓ Public private health system ✓ Multi-cultural population ✓ Population receptive to testing / participation ✓ R&D Tax incentives Key Drivers - Australia The strategy of getting a greater “share of wallet” expands on 3 vector's, more therapeutic areas, more services to each customer, and more customers through organic (SaMD) or acquisitive (buy expertise & footprint) growth. Oncology/Hematology, 28% Neurology, 8% Infectious Disease (Therapeutic), 8% Endocrinolo gy, 6% Rheumatology, 5% Cardiovascular, 5% Dermatology, 5% Infectious Disease (Immunization), 5% Respiratory, 4% Ophthalmology, 4% Psychiatry, 3% Hematology, 3% Gastroi ntestin al, 2% Reprod uctive Health, 2% Hepatol ogy, 2% Other, 10% % $ SPENDING IN GLOBAL CLINICAL TRIALS BY THERAPEUTIC AREA More Customers More sites – Geographic (Australia then overseas) – More phases – Later stage to Phase 1 More devices and imaging endpoints More services provided in-house Other services More Services More Therapeutic Areas More Customers Examples of early success… Therapeutic Area Services Work Won Opportunities Haematology First Liver / Spleen Iron, then Site services - Trialswest Haematology First Liver / Spleen Iron, then central reading & image storage Metabolic First CRO, then Site services – TrialsWest, & Liver fat & Stiffness Obesity First Liver fat & VAT / SAT, then CRO & Site Services ENT First site services, then CRO Services Australian global pharma US global pharma Top 10 Indian global pharma US Biotech In the SaMD business we need to develop meaningful imaging endpoints for trials that may become standalone diagnostic devices…paid for by customers Time Revenue LIC Fibrosis Fat MRE VAT/SAT Other Reg Cleared (FDA,MDR,TGA) Investigational Early commercialisation through clinical trial use Develop both novel (IP Patent) and standard devices / endpoints for investigational use paid for by customers. Bootstrap R&D and product development through use to pay for the path to regulatory cleared devices More endpoints / devices more rapidly Bring more products to market more rapidly to drive revenue through development of both novel and standardized devices / endpoints across more therapeutic areas focusing on MRI We have improved productivity and customer connectivity though investment in technology Better customer integration Artificial Intelligence Improved Systems Resonance Bridge Better integrated with customers directly using the Resonance Bridge. Software bridge allows a direct, immediate 2-way connection to our customers PACS. Automatically sends a job to us when it is completed at imaging, it also; • Strips PHI • Encrypts record • Immediately returns report in DICOM format into customer PACS Drastic improvement in cybersecurity profile Automation Increase capacity of the business through automation including use of advanced AI products. Significantly increase capacity (10x) of SaMD business. New tech stack to modernize analysis, provide a platform for more rapid product development and deployment Realize full benefit of AI products and tools to scale Efficiencies Focus on efficiencies across group Significant headcount out during fy25 through process efficiencies Future focus on creating efficiencies to drive; • Capacity expansion • Margin accretion Resonance Bridge both natively integrates our products in customer workflows and significantly improves cyber security Benefits • Improved cybersecurity • Immediacy • Native workflow integration – no work for customer • New tech stack and bridge allow; • Multiple analysis centres, ie northern / southern hemisphere • 24/7 turnarounds • Distributed radiologists / specialists / analysts reading service with bespoke worklists Resonance Bridge Automation Our deep domain expertise and reputation resonates with customers… • Client roster of blue-chip global pharma • Looked to as trusted advisor in areas of trial design and end points • Deep experience across 20 years of participating in clinical trials • Profile attracts emerging biotech & pharma • Haematology • Hepatology • Metabolic disease and obesity • Respiratory • Vaccines • Renal • ENT • Cardiology • Chronic Pain • Global regulatory cleared products; • FDA, MDR, TGA • Quality system • GCP compliant Clinical Trial Expertise & Reputation Strong Quality & Regulatory Capability Deep Expertise in Therapeutic Areas & MRI NORTH AMERICA 19% EMEA 56% ASIA PAC 25% Our global pharma and hospital customers are largely in the northern hemisphere working on later stage global clinical trials % of FY25 Revenue Our clinical trial customers are global pharma. Trial protocols are standardized across each trial globally and are run according to GCP. These factors make Resonances’ expansion geographically agnostic Growth Opportunities SaMD Business ✓ More devices to existing & new customers ✓ Sale of AI devices to emerging markets (China, India) ✓ Expand into new therapeutic areas (MRI focussed) TrialsWest ✓ Greenfield geographic expansion (Perth then Australia) ✓ Expand into new therapeutic areas ✓ Expand into earlier stage trials (phase 1) ✓ Acquisitive expansion US & Europe (same customers same trials) to participate in larger phase 3 trials for FDA approvals Resonance Clinical ✓ Win new Australian trials ✓ Bring new customers to Australia for early-stage trials (Indian Pharma, smaller US biotech) Australian turnkey package ✓ Acquire / establish US / European presence (along with imaging & trial sites) bring customers to US/Europe for late-stage FDA/MDR trials, greater share of wallet in existing global trials we participate in Growth imperatives – Project 50:28. In FY24 we had an ambition to achieve $50m in annual revenue by the end of FY28 • Automation • Fibrosis + new endpoints • New Countries • Acquisitions in new therapeutic areas • New Customers • New therapeutic areas • Repeat business • Large contract sizes • New Geographies • Greenfield Expansion (4-5 in WA, then Australia) • Acquisitions (Australia then US / Europe) • New therapeutic areas • Earlier stage trials (phase 1) Other strategic opportunities SaMD, 34% Resonance Clinical, 33% TrialsWest, 33% 17 Resonance Health Financial Overview Benjamin Carruthers CFO Resonance Health specialises in providing central imaging (SaMD) services, contract research organisation (CRO) services and investigator site (TrialsWest) services to global pharmaceutical and biotechnology companies, hospitals and radiology centres. “We only enter businesses where we have deep domain expertise and reputation or purchase adjacent businesses we understand” Investigator Sites Central Imaging Vendor Contract Research Organisation Analysis of MR images to non-invasively measure liver iron, cardiac iron and liver fat measurements Local Clinical Research Organisation (‘CRO’) offering end-to-end management of clinical trials in Australia Identification, recruitment and day-to- day management of participants during the conduct of clinical trials Financial imperatives Entrenched profitability ✓ Build revenue base ✓ Disciplined cost control ✓ Business transformation providing strong financial base with significant growth potential Generate strong FCF ✓ Operating cash flow positive ✓ Low sustaining capex ✓ Accretive expansion capex & acquisitions Target EBITDA Margin Range ~ 25% ✓ Established overhead base that can be leveraged ✓ Revenue growth across three business segments, looking to drive margin uplift at full revenue scale ✓ Greater share of wallet reduces customer acquisition costs and increases margin capture / customer / project Responsible growth ✓ Conservative gearing metrics - target Net Debt EBITDA < 2x (long term ~ 1.5x) ✓ Maintain a strong balance sheet – financial strength and greater flexibility to pursue attractive opportunities ✓ Properly support and embed new business streams and acquisitions Business transformation well underway *Normalised Operating EBITDA = Statutory Net Loss – (R&D tax Credit, FX gain, Share based payments) + (Depreciation, amortisation & net interest expense, one-off restructuring & transaction costs, and unearned income). Strength of the business model Key focus is on creating value for clients and Resonance Health ✓ Leveraging deep experience across the clinical trial ecosystem ✓ Execution capability and ability to add value to trial design and roll out ✓ Greater share of wallet ✓ Creation of new products for specific trials – low R&D effort with greater application possibilities ✓ Transition from clinical use only products to registered broad retail market products where it makes sense ✓ Access to the Australian clinical trial market which is a quicker and cheaper alternative to the USA/Europe Being growth ready The business is actively preparing for its next growth phase ✓ Established overhead base ✓ Experienced management team ✓ Clear business strategy with three complementary business segments ✓ Deep experience across SaMD medical imaging products and clinical trials ✓ Ability to access to debt and equity Guidance FY26 FY26 Guidance $M Revenue 17 Underlying EBITDA 2 ✓ Target EBITDA margins over coming periods ~25% as operational leverage drives margin expansion. ✓ Operationally cashflow positive. ✓ Significant potential upside from conservative assumptions. Assumptions: ✓ No new TrialsWest sites during period ✓ No new contract wins in Resonance Clinical business ✓ Geographical expansion not included ✓ No contribution from new Non-Invasive Fibrosis device ✓ Acquisition pipeline not included ✓ Existing contracted clinical trials run their full expected duration 24 Resonance Health Dr Helen Pavitt VP, Clinical Trials TrialsWest Overview Other Staff (18) Senior Leadership Team Dr Helen Pavitt Head of Clinical Trials Prof Peter Bremner Medical Director Dr Kenneth Macpherson Clinical Research Physician Michelle Davies Clinical Trial Manager – Spearwood Michaela Peck Clinical Trial Manager – Osborne Park Bibin George Clinical Trial Manager – Mandurah Principal Investigators, Clinical Research Physicians, Research Nurses, Clinical Trial Co-ordinators, Clinical Trial Assistant, Phlebotomist, Recruitment Specialists, Study Start-up Associate. All staff are GCP Certified TrialsWest Clinic Locations What does a Clinical Trial Investigator Site Do? Therapeutic Area Expertise VACCINES Meningococcal, RSV, influenza, pneumococcal RESPIRATORY Asthma, COPD, ILD, bronchiectasis, chronic cough GASTROENTEROLOGY/HEPATOLOGY Iron-related liver disease, Hepatitis C METABOLIC DISEASES Obesity, MASLD, MASH CHRONIC PAIN ENT Chronic Rhinosinusitis, Nasal Polyposis HAEMATOLOGY Sickle Cell Anaemia, Thalassaemia, MDS CARDIOLOGY Heart Failure Prevention RENAL Chronic Kidney Disease Partnerships with Global Pharma and CROs TrialsWest Revenue Growth 31 Resonance Health Dr Helen Pavitt VP, Clinical Trials Resonance Clinical Overview Other Staff Senior Leadership Team Dr Helen Pavitt VP, Clinical Trials Michelle Summerill Clinical Operations Manager Jessica Choi Clinical Project Manager Internal Clinical Research Associates, Clinical Research Administrators, Quality Manager, Quality Associate. Contractors Biostatisticians, Regulatory Specialist, Toxicologist, Data Managers. What does a Contract Research Organisation (CRO) Do? Current Projects & Future Opportunities SF-CSP-001 (MASLD): Commenced Dec 2023 Completed Mar 2025 SF-CSP-002 (At risk-MASH): Commenced Dec 2024 Due to complete Jul 2026 Resonance Clinical Revenue Growth While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs Both the number of trials and the size of the market for GLP-1 like drug trials is seeing rapid growth. Resonance’s deep expertise in liver and related metabolic / obesity areas is sort after in this space across all 3 businesses Disclaimer Forward Looking Statements This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health’s products and services. These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law. This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of or be relied on in any connection with any contract or commitment. The information in this presentation does not take into account the objectives, financial situation or individual needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision. To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other person’s accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it. Contact Us info@resonancehealth.com +61 8 9286 5300 resonancehealth.com resonance-health-ltd/